Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd.



          XTL Biopharmaceuticals Acquires Stake in Proteologics Ltd.

PR Newswire

HERZLIYA, Israel, November 26, 2012

HERZLIYA, Israel, November 26, 2012 /PRNewswire/ --

XTL Biopharmaceuticals Ltd. (TASE: XTL) (OTC: XTLBY) (the "Company"), a
biopharmaceutical development company, announced on November 21^st that it has
acquired 4,620,356 shares, of Proteologics Ltd. (TASE: PRTL) (hereinafter:
"the Shares" and "Proteologics", respectively), from Teva Pharmaceutical
Industries Ltd. (NYSE: TEVA, TASE: TEVA) (hereinafter: "Teva") in
consideration for an amount of approximately NIS 6.5 million, which represents
an amount of NIS 1.405 per Share (approximately 22% premium). The Shares
represent all of Teva's shares in Proteologics and represent approximately
31.35% of Proteologics issued and outstanding share capital.

Proteologics is a biopharmaceutical publically traded company listed on the
Tel Aviv Stock Exchange, which is in the business of discovery and research of
drugs that are active on various components of the UBIQUITIN system, which was
discovered by Drs. Avram Hershko and Aaron Ciechanover - 2004 Nobel Prize in
Chemistry laureates for the discovery of the UBIQUITIN system.

About XTL Biopharmaceuticals, Ltd. ("XTL")

XTL Biopharmaceuticals, Ltd., a biopharmaceutical company, focuses on the
acquisition, development, and commercialization of pharmaceutical products for
the treatment of clinical unmet needs. XTL is focused on late stage clinical
development of drugs for the treatment of multiple myeloma, schizophrenia, and
hepatitis C.

XTL's lead drug candidate, rHuEPO, for the treatment of multiple myeloma blood
cancer, was granted an orphan drug designation from the FDA. rHuEPO has been
approved for marketing by the FDA and has for many years been sold for
billions of dollars across the world for the treatment of severe anemia.

XTL is a public company traded on the Tel Aviv Stock Exchange (TASE: XTL) and
its ADRs are quoted in the US on the Pink Sheets (OTC: XTLBY).

For additional information about Proteologics, please visit:
http://www.proteologics.com

Contact:
Investor Relations, XTL Biopharmaceuticals Ltd.
Tel: +972-9-955-7080, Email: ir@xtlbio.com

SOURCE XTL Biopharmaceuticals Ltd
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement